Inogen, Inc. (NASDAQ:INGN) Short Interest Up 8.8% in January

Inogen, Inc. (NASDAQ:INGN) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 798,600 shares, a growth of 8.8% from the January 15th total of 734,000 shares. Based on an average daily volume of 224,800 shares, the days-to-cover ratio is currently 3.6 days.

Inogen Price Performance

NASDAQ:INGN traded down $0.02 during mid-day trading on Monday, reaching $10.64. 340,965 shares of the company’s stock traded hands, compared to its average volume of 262,340. The company has a 50 day moving average price of $10.09 and a 200-day moving average price of $10.26. The firm has a market capitalization of $253.44 million, a price-to-earnings ratio of -4.73 and a beta of 1.02. Inogen has a 12-month low of $5.82 and a 12-month high of $13.33.

Analysts Set New Price Targets

Several brokerages have recently issued reports on INGN. Needham & Company LLC restated a “hold” rating on shares of Inogen in a report on Thursday, January 30th. StockNews.com raised shares of Inogen from a “hold” rating to a “buy” rating in a report on Monday, February 10th.

Hedge Funds Weigh In On Inogen

Several hedge funds have recently made changes to their positions in INGN. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Inogen by 312.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after acquiring an additional 132,287 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Inogen by 2.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock worth $8,692,000 after purchasing an additional 23,891 shares during the period. Barclays PLC boosted its stake in shares of Inogen by 72.9% during the 3rd quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock valued at $539,000 after purchasing an additional 23,398 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Inogen by 1.1% during the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock valued at $5,377,000 after buying an additional 5,921 shares during the period. Finally, Franklin Resources Inc. bought a new position in Inogen in the third quarter worth about $139,000. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.